China Resources Double-Crane Pharmaceutical (SHA:600062) posted 2024 net profit attributable to shareholders of 1.63 billion yuan, down 2.6% from 1.67 billion yuan the previous year.
Earnings per share declined to 1.5838 yuan from 1.6306 yuan, according to a filing with the Shanghai bourse.
The company's revenue inched down 0.9% year over year to 11.2 billion yuan from 11.3 billion yuan.
The board declared a cash distribution of 0.371 yuan per share for 2024.
Shares of the company were down 3% in recent trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。